Waukesha County funding helps elderly, those with disabilities with lift program
The Aging and Disability Resource Center of Waukesha County helps older people and those with disabilities.
The lift program grant is funded by the Wisconsin Department of Transportation.
There is no income requirement for this program, but you have to be a Waukesha County resident 18 and older to apply.
WAUKESHA, Wis. - There is free money available to help older people and those with disabilities in Waukesha County get around easily.
Local perspective
Wherever 74-year-old Ann Blackney goes, she needs a little help getting there. But without a boost, her scooter is just too heavy to lift on her own.
Blackney has joint pain and Parkinson's disease.
FREE DOWNLOAD: Get breaking news alerts in the FOX LOCAL Mobile app for iOS or Android
What we know
She is one of 30 people so far using Waukesha County's Vehicle Modification Program, administered by the Aging and Disability Resource Center (ADRC).
Sarah Pfeiffle is the outreach coordinator for Waukesha County's ADRC. The group received $100,000 from the Wisconsin Department of Transportation to help add a mechanical lift to the vehicles of eligible residents.
"We started this as a pilot program in September of last year," Pfeiffle said.
Blackney's lift would have cost her $5,000. The grant covered the entire cost.
"We live in an apartment complex," Blackney said. "I could go around the walkways with it, but other than that, I was pretty well stuck."
Pfeiffle said there's still money left to help others. And soon, she said, there could be many more people in need.
Dig deeper
In the next 25 years, Pfeiffle said one out of every three people in Waukesha County will be 60 years or older. Additionally, a recent ADRC study found 14% of people in the county aged 50 and older reported feelings of loneliness.
SIGN UP TODAY: Get daily headlines, breaking news emails from FOX6 News
"We want folks to get out there," Pfeiffle said. "We know someone who is socially isolated or experiencing loneliness, their risk factors for complicated health issues increase."
Blackney said it was only a matter of weeks before her grant was approved.
"I'm so much more mobile now. Go out and around," she said. "It's really fun. Really fun!"
What you can do
There is no income requirement for this program, but you have to be a Waukesha County resident 18 and older to apply. You also have to have a disability that impairs your ability to drive, ride or access a personal vehicle – or requires the use of a mobility device or transfer aide which cannot be accommodated in a personal vehicle without modifications.
Click to open this PDF in a new window.
Anyone interested should reach out to the ADRC of Waukesha County.
The Source
The information in this post was collected and produced by FOX6 News.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
4 days ago
- Newsweek
Parkinson's Breakthrough Could Help Prevent Brain Cell Loss
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A new treatment for one type of Parkinson's disease may be on the horizon after researchers discovered a "brake" that can halt cell death. The study, led by researchers from Stanford University, California, involved a form of the neurodegenerative disorder that is caused by a single genetic mutation. This mutation causes an excess of a protein that interferes with the brain's ability to protect itself. Inhibiting this protein, the team found, can halt the damage and even allow dying neurons to recover. "These findings suggest that it might be possible to improve, not just stabilize, the condition of patients with Parkinson's disease," said paper author and Stanford biochemist professor Suzanne Pfeffer in a statement. Key, however, will be "if patients can be identified early enough," she added. While Parkinson's most recognizable symptom might be resting tremors, the earliest signs of the disease typically manifest some 15 years earlier. These first signs, Pfeffer said, include constipation, a loss of smell and REM sleep behavior disorder, a condition in which people act out their dreams while sleeping. Artist's impression of neurons in the brain. Artist's impression of neurons in the brain. FlashMovie/iStock / Getty Images Plus In the U.S, it is estimated that some 1.1 million people are living with Parkinson's disease—a figure only expected to rise in the near future, according to the Parkinson's Foundation. As Pfeffer and colleagues explain, around a quarter of all cases are caused by genetic mutations, with one of the most common being one that increases the activity of an enzyme called leucine-rich repeat kinase 2 (LRRK2). Too much LRRK2 in the brain changes the structure of cells by causing them to lose their "antenna" (technically the primary cilia) that allows them to send and receive chemical messages. In a healthy brain, communications are relayed back and forth between dopamine neurons in two regions of the brain known as the striatum and the substantia nigra. When dopamine neurons are stressed, they release a protein-based signal in the striatum called sonic hedgehog (after the video game character)—this causes neurons and support cells to produce so-called neuroprotective factors that shield other cells from dying. When LRRK2 activity crosses a certain threshold, the loss of the primary cilia in the cells of the striatum prevents them from receiving the sonic hedgehog signal; as a result, the neuroprotective factors are not produced. "Many kinds of processes necessary for cells to survive are regulated through cilia sending and receiving signals," explained Pfeffer. "The cells in the striatum that secrete neuroprotective factors in response to hedgehog signals also need hedgehog to survive. "We think that when cells have lost their cilia, they are also on the pathway to death because they need cilia to receive signals that keep them alive." A diagram shows how neurons (blue) rooted in the substantia nigra provide dopamine (dark green dots) to striatal neurons (red). A diagram shows how neurons (blue) rooted in the substantia nigra provide dopamine (dark green dots) to striatal neurons (red). Emily Moskal / Stanford Medicine It is possible to combat an excess of LRRK2 using a so-called "MLi-2 LRRK2 kinase inhibitor," a molecule that attaches to the enzyme and reduces its activity. In their study, Pfeffer and colleagues set out to test whether this inhibitor could also reverse the effects of too much LRRK2, as well as whether it was even possible for fully mature neurons and supportive glia to regrow lost cilia and regain their communication ability. At first, the results were not promising. The team gave the inhibitor for two weeks to mice that had the LRRK2 mutation (and show symptoms consistent with early Parkinson's disease)—to no effect. However, the researchers were inspired by recent studies into sleep-wake cycles, which found that the primary cilia on the mature cells involved grew and shrank every 12 hours. "The findings that other non-dividing cells grow cilia made us realize that it was theoretically possible for the inhibitor to work," said Pfeffer. Inspired by this, the team decided to try giving the mice the inhibitor for a longer time—with the results at three months being "astounding," the biochemist added. The longer treatment saw the percentage of striatal neurons and glia with primary cilia in the mice with the mutation increase to the same level as regular, healthy mice. This had the effect of restoring communication between the dopamine neurons and the striatum, leading to the normal secretion of neuroprotective factors. The researchers also found that the level of hedgehog signaling from the dopamine neurons decreased—suggesting that they were under less stress. Moreover, the density of dopamine nerve endings in the mice's striatum was found to double, suggesting that neurons which had been in the process of dying had recovered. LRRK2 inhibition decreased stress in dopamine neurons in mice models of Parkinson's (top right vs. bottom right—with healthy mice on the left for comparison.) LRRK2 inhibition decreased stress in dopamine neurons in mice models of Parkinson's (top right vs. bottom right—with healthy mice on the left for comparison.) Ebsy Jaimon & Suzanne Pfeffer With their initial study complete, the researchers say that their next step would be to determine whether other forms of Parkinson's that are not associated with the LRRK2 mutation could also benefit from the new treatment. This is possible, Pfeffer explains, because the mutation is not the only way to end up with an overactive LRRK2 enzyme. In fact, she added, the inhibitor treatment might even help with other neurodegenerative diseases. "We are so excited about these findings. They suggest this approach has great promise to help patients in terms of restoring neuronal activity in this brain circuit, said Pfeffer. She concluded: "There are multiple LRRK2 inhibitor clinical trials underway—and our hope is that these findings in mice will hold true for patients in the future." Do you have a tip on a health story that Newsweek should be covering? Do you have a question about Parkinson's disease? Let us know via health@ Reference Jaimon, E., Lin, Y.-E., Tonelli, F., Antico, O., Alessi, D. R., & Pfeffer, S. R. (2025). Restoration of striatal neuroprotective pathways by kinase inhibitor treatment of Parkinson's disease–linked LRRK2-mutant mice. Science Signaling, 18(793).
New York Post
4 days ago
- New York Post
Living near a golf course is linked to Parkinson's risk in new study as some cite limitations
Advertisement If living near a golf course seems scenic and relaxing, it may also be linked to a higher risk of Parkinson's disease, according to a surprising new study that comes with some limitations. Led by the Barrow Neurological Institute in Arizona, along with Mayo Clinic, the study found that the greatest risk was found among those who live within one to three miles of a golf course. 'The strongest effects were in municipal water service areas with a golf course and in regions with vulnerable groundwater based on the bedrock and topography,' lead study author Brittany Krzyzanowski, Ph.D., assistant professor at the Barrow Neurological Institute, told Fox News Digital. Advertisement 'These findings suggest that pesticides applied to golf courses may play a role in the incidence of PD [Parkinson's disease] for nearby residents,' the researchers concluded in the study, which was published in JAMA Network Open. The case-control study analyzed data from 419 Parkinson's patients averaging 73 years of age and living near 139 golf courses in southern Minnesota and western Wisconsin. They then made comparisons to control data from the Rochester Epidemiology Project from 1991 to 2015. 5 Led by the Barrow Neurological Institute in Arizona, along with the Mayo Clinic, the study found that the greatest risk was among those who live within one to three miles of a golf course. Peakstock – Advertisement 'We had accurate data on golf course locations, and we could accurately determine the source of an individual's drinking water – whether that be municipal water or private well water,' Krzyzanowski noted. Living within one mile of a golf course was associated with 126% increased odds of developing the neurological disease compared to living more than six miles away, the study found. People living near water service areas with a golf course had nearly twice the risk of developing Parkinson's compared with individuals in water service areas without golf courses. Those living in water service areas with a golf course in vulnerable groundwater regions had an 82% higher risk, according to the findings. Advertisement (Vulnerable groundwater is more susceptible to contamination from human activities and environmental factors.) The associations remained even after the researchers adjusted for age and income, which suggests there could be something more than demographics driving the relationship between golf course proximity and risk of Parkinson's disease, Krzyzanowski noted. 'We speculate that pesticides might play a role; however, we didn't include data on pesticides in this study, so future research is needed to better understand what's going on,' she said. 5 The case-control study analyzed data from 419 Parkinson's patients averaging 73 years of age and living near 139 golf courses in southern Minnesota and western Wisconsin. Reese Coop/ – Dr. Mary Ann Picone, medical director of the MS Center at Holy Name Medical Center in Teaneck, New Jersey, was not involved in the study but shared her opinion of the findings. 'There has often been discussion regarding risks for development of Parkinson's disease and environmental agents such as pesticides,' she told Fox News Digital. 'Further research is needed with larger groups of patients, but this study does increase the concern about the association between pesticide exposure and risk of Parkinson's, especially within a one- to three-mile radius and groundwater and well vulnerability.' Airborne exposure to the pesticides was also a factor, she added. Potential limitations Advertisement The main limitation of the study is that it is not possible to quantify the amount of exposure each person receives, according to Dr. Rodolfo Savica, Mayo Clinic neurologist and senior author of the study. 'Unfortunately, there are many other aspects as well that can interfere with developing a disease,' he told Fox News Digital. 'Despite that, we are trying our best to contemplate and adjust for any possible additional information, but sometimes that is not possible.' 5 Living within one mile of a golf course was associated with 126% increased odds of developing the neurological disease compared to living more than six miles away, the study found. ipopba – Advertisement The study was limited to a region with hot and humid summers, specifically southern Minnesota and western Wisconsin, where golf courses may have applied pesticides with more frequency compared to other geographic regions. 'Therefore, our results might not generalize to other areas,' the study lead noted. Other relevant Parkinson's risk factors, such as head trauma history and genetic predisposition, were not accounted for, Picone noted. Krzyzanowski also pointed out that Parkinson's disease develops many decades after exposure, so the study aimed to estimate exposure from long ago. Advertisement 'If pesticides were involved, they would be the ones sprayed a long time ago and that might be different from what's being sprayed today,' she said. 5 The associations remained even after the researchers adjusted for age and income, suggesting that something more than demographics may be driving the relationship between golf course proximity and the risk of Parkinson's disease. Thomas T/ – Picone agreed that because this study looked back to 2013, it is possible that different pesticides used before 2013 were not tracked. 'However, this study does provide evidence for an association between living on a golf course and pesticide groundwater exposure and risk of Parkinson's development, and does raise concern and the need for larger population sample research,' she shared with Fox News Digital. Advertisement Krzyzanowski added that because this was an observational study, the researchers couldn't make causal conclusions about the results. 'If you're worried about exposure of any kind, you should consult with your doctor,' she advised. Industry spokespeople respond A spokesperson from the Golf Course Superintendents Association of America, headquartered in Lawrence, Kansas, provided a statement to Fox News Digital in response to the study. 5 Living within one mile of a golf course was associated with 126% increased odds of developing the neurological disease compared to living more than six miles away, the study found. Pixel-Shot – 'Public health experts and researchers who have reviewed the study have noted that the study's methodological limitations make it difficult to draw conclusions from the data. As noted by the authors of the study, the role of pesticide exposure from golf courses in Parkinson's disease risk remains unclear. Without the methodological gaps being filled, the hypothesis linking golf-course pesticide exposure to Parkinson's Disease remains speculative.' The spokesperson noted that the US Environmental Protection Agency (EPA) rigorously tests and registers the pesticides that the golf industry uses to maintain healthy golf course turf. 'Pesticides registered by the EPA do not, according to the top researchers in their field, create unreasonable adverse effects to human health and the environment when used according to label directions,' the spokesperson continued. 'Golf course superintendents are leading practitioners of integrated pest management, a philosophy that reduces the potential environmental risks of pesticide usage.' Mayo Clinic's Savica recommended that older adults continue to stay active, which is crucial for their well-being. 'I recommend people continue to play sports outdoors and enjoy the sociality of any activity, including playing golf,' he said. 'On the other hand, I would recommend that people be very careful and avoid exposure to places where we know there can be an interaction between pesticides and contaminants.'
Business Upturn
4 days ago
- Business Upturn
DRC Medicine Ltd. Announces the Business Combination Agreement with Ribbon Acquisition Corp.
Combined Company Expected to be Listed on NASDAQ Global Market DRC Medicine Ltd. ('DRC Medicine' or the 'Company'), is an innovative healthcare and biotechnology company headquartered in Japan, focused on the research, development, and commercialization of advanced medical technologies that address significant global health challenges. The Company is best known for its proprietary Hydro Silver Titanium® technology, initially applied in consumer hygiene products such as masks and towels, and now being advanced to obtain medical device certification as among the world's first therapeutic masks for seasonal allergic rhinitis. Combined company to have an implied initial pro forma equity value of approximately $422.15 Million, (assuming no redemptions) and the transaction is expected to deliver cash proceeds of around $50.42 Million to DRC Medicine (assuming no redemptions) to fund DRC Medicine's business and operations, which include devices' clinical trial and certification. Current DRC Medicine shareholders will retain 100% of their equity and will continue to own approximately 82.91% of the combined company on a pro forma basis, assuming no redemptions by Ribbon's shareholder. Tokyo, June 30, 2025 (GLOBE NEWSWIRE) — DRC Medicine Ltd., an innovative healthcare and biotechnology company based in Tokyo, Japan ('DRC' or the 'Company'), announced today that it has entered into a business combination agreement (the 'Business Combination Agreement') with Ribbon Acquisition Corp. (NASDAQ: RIBB) ('Ribbon'), a special purpose acquisition company, DRC Medicine Inc., a Delaware company limited by shares (DRC Medicine) and DRC Merger Inc. ('Merger Sub'), a Delaware company limited by shares and a directly owned subsidiary of DRC Medicine, which would result in DRC Medicine becoming a publicly-traded company (the 'Proposed Transaction'). DRC Medicine Ltd. is an innovative healthcare and biotechnology company headquartered in Japan, focused on the research, development, and commercialization of advanced medical technologies that address significant global health challenges. The Company is best known for its proprietary Hydro Silver Titanium® technology, initially applied in consumer hygiene products such as masks and towels, and now being advanced to obtain medical device certification as among the world's first therapeutic masks for seasonal allergic rhinitis. In addition to medical devices, the Company is developing a pipeline of In Vitro Diagnostic ('IVD') kits for infectious diseases and allergen detection, combining its world-only cell-free protein synthesis technology leveraging AI powered Apps and is in final negotiation in acquiring an innovative ATP-enhancing drug for Parkinson's disease drugs development company, the drug is currently in clinical trials. This diverse portfolio is driven by a strong focus on unmet medical needs, AI-assisted discovery, and global healthcare infrastructure transformation. For more information, visit and Dr. Marumi Okazaki, President & CEO of DRC, said: 'This transaction will give us the resources that will enable us to capture the positive trends in our industry. Given the growth of airborne allergens, respiratory diseases and infectious diseases, increasing demand for better respiratory protection mask and faster and a more accurate IVD kits, we intend to invest in more IVD kits paired with AI-powered Apps in achieving universal diagnostics to empower the general public in guarding their health and fight against allergen, respiratory diseases and infectious diseases as well as catapult our research and development, production capabilities to meet the rising demand for better respiratory protection mask and AI-powered IVD kits.' Mr. Angshuman (Bubai) Ghosh, Chairman/CEO of Ribbon, said, ' This business combination agreement with DRC is a great opportunity to enter into an exciting and accelerating growth healthcare and biotechnology industry. We believe its highly capable and experienced management team with all of the founders with substantial experience in developing innovative technologies, supported by their technology-savvy specialists and R&D team who are committed to pioneering innovations, will enable DRC to continuously innovate and advance their healthcare and biotechnology applications to gain a greater foothold in the global market.' Transaction Overview As a part of the Proposed Transaction, an intermediate holding company incorporated in Japan (the 'Intermediate Co.' will acquire the shares of DRC Medicine, after which the Intermediate Co. will engage in a share exchange transaction with the shareholders of the Company, such that the Company will become a wholly-owned subsidiary of Intermediate Co. and the shareholders of the Company will become shareholders of DRC Medicine (the 'DRC Restructuring'). Following the consummation of the DRC Restructuring and subject to the terms and conditions of the Business Combination Agreement, Ribbon will merge with and into the Merger Sub, with Merger Sub continuing as the surviving company and remaining a wholly owned subsidiary of DRC Medicine. The Proposed Transaction implies a pre-money equity value of US$350 million of DRC on a fully diluted basis, and is expected to provide DRC with access to approximately US$50 million cash from Ribbon's IPO proceeds held in trust, assuming no redemption by Ribbon's shareholders in connection with the current and future proxy exercises and prior to the payment of any transaction expenses. The parties will cooperate in connection with any financing arrangement the parties seek in connection with the Proposed Transaction. Advisors A.G.P./Alliance Global Partners serves as the financial advisor and lead capital markets advisor to Ribbon. Geneva Capital Group serves as the financial advisor to DRC. Celine & Partners serves as the legal advisor to Ribbon. Ross Law Group serves as the legal advisor to DRC. About DRC Medicine Ltd . Founded in 2007, DRC is an innovative healthcare and biotechnology company headquartered in Japan, focused on the research, development, and commercialization of advanced medical technologies that address significant global health challenges. The Company is best known for its proprietary Hydro Silver Titanium® technology, initially applied in consumer hygiene products such as masks and towels, and now being advanced to obtain medical device certification as among the world's first therapeutic masks for seasonal allergic rhinitis . In addition to medical devices, the Company is developing a pipeline of In Vitro Diagnostic ('IVD') kits for infectious diseases and allergen detection, combining its world-only cell-free protein synthesis technology leveraging AI powered Apps and is in final negotiation in acquiring an innovative ATP-enhancing drug for Parkinson's disease. About Ribbon Acquisition Corp . Ribbon is a blank check company whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. While Ribbon intends to conduct a global search for target businesses without being limited by geographic region, certain executive officers and independent directors are based in Hong Kong, and certain executive officers have experience investing in and building businesses in the Asia Pacific region and have a deep understanding of the region's business environment, regulations, regulatory bodies and culture. Ribbon will not undertake an initial business combination with any company being based in or having the majority of the company's operations in Greater China. Ribbon is led by Mr. Angshuman (Bubai) Ghosh, Ribbon's Chief Executive Officer, and Ms. Zhiyang (Anna) Zhou, Ribbon's Chief Financial Officer. Important Additional Information Regarding the Transaction Will Be Filed With the SEC This press release relates to the proposed business combination between Ribbon Acquisition Corp. and DRC Medicine Ltd.. This press release does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. DRC intends to file a Registration Statement on Form S-4 with the SEC, which will include a document that serves as a joint prospectus and proxy statement, referred to as a proxy statement/prospectus. A proxy statement/prospectus will be sent to all Ribbon shareholders. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom. Ribbon and DRC will also file other documents regarding the proposed business combination with the SEC. This press release does not contain all the information that should be considered concerning the proposed business combination and is not intended to form the basis of any investment decision or any other decision in respect of the business combination. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS OF RIBBON ARE URGED TO READ THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED BUSINESS COMBINATION AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED BUSINESS COMBINATION. Investors and security holders will be able to obtain free copies of the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by Ribbon and DRC through the website maintained by the SEC at The documents filed by Ribbon and DRC with the SEC also may be obtained free of charge upon written request to Ribbon Acquisition Corp., Central Park Tower LaTour Shinjuku Room 3001, 6-15-1 Nishi Shinjuku, Shinjuku-ku Tokyo 160-0023. Participants in the Solicitations Ribbon, DRC and their respective directors, executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies from Ribbon's shareholders in connection with the proposed business combination. You can find information about Ribbon's directors and executive officers and their interest in Ribbon in Ribbon's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was originally filed with the SEC on April 1, 2025. A list of the names of the directors, executive officers, other members of management and employees of Ribbon and DRC, as well as information regarding their interests in the business combination, will be contained in the Registration Statement on Form S-4 to be filed with the SEC by DRC. Additional information regarding the interests of such potential participants in the solicitation process may also be included in other relevant documents when they are filed with the SEC. You may obtain free copies of these documents from the sources indicated above. Caution About Forward-Looking Statements This press release may contain forward-looking statements within the meaning of section 27A of the U.S. Securities Act of 1933, as amended (the 'Securities Act'), and section 21E of the U.S. Securities Exchange Act of 1934 ('Exchange Act') that are based on beliefs and assumptions and on information currently available to Ribbon and DRC. These forward-looking statements are based on Ribbon's and DRC's expectations and beliefs concerning future events and involve risks and uncertainties that may cause actual results to differ materially from current expectations. In some cases, you can identify forward-looking statements by the following words: 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing,' 'target,' 'seek' or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Any statements that refer to expectations, projections or other characterizations of future events or circumstances, including projections of market opportunity and market share, the capability of DRC's business plans including its plans to expand, the anticipated enterprise value of the combined company following the consummation of the proposed business combination, anticipated benefits of the proposed business combination and expectations related to the terms and timing of the proposed business combination, are also forward-looking statements. Although each of Ribbon and DRC believes that it has a reasonable basis for each forward-looking statement contained in this communication, each of Ribbon and DRC cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. These factors are difficult to predict accurately and may be beyond Ribbon's and DRC's control. In addition, there will be risks and uncertainties described in the proxy statement/prospectus on Form S-4 relating to the proposed business combination, which is expected to be filed by DRC with the SEC and other documents filed by Ribbon or DRC from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those expressed or implied in the forward-looking statements. There may be additional risks that neither Ribbon or DRC presently know or that Ribbon and DRC currently believe are immaterial and that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by Ribbon or DRC, their respective directors, officers or employees or any other person that Ribbon and DRC will achieve their objectives and plans in any specified time frame, or at all. Forward-looking statements in this communication or elsewhere speak only as of the date made. New uncertainties and risks arise from time to time, and it is impossible for Ribbon or DRC to predict these events or how they may affect Ribbon or DRC. Except as required by law, neither Ribbon nor DRC has any duty to, and does not intend to, update or revise the forward-looking statements in this communication or elsewhere after the date this communication is issued. In light of these risks and uncertainties, investors should keep in mind that results, events or developments discussed in any forward-looking statement made in this communication may not occur. Uncertainties and risk factors that could affect Ribbon's and DRC's future performance and cause results to differ from the forward-looking statements in this release include, but are not limited to: the occurrence of any event, change or other circumstances that could give rise to the termination of the business combination; the outcome of any legal proceedings that may be instituted against Ribbon or DRC, the combined company or others following the announcement of the business combination; the inability to complete the business combination due to the failure to obtain approval of the shareholders of Ribbon or to satisfy other conditions to closing; changes to the proposed structure of the business combination that may be required or appropriate as a result of applicable laws or regulations; the ability to meet stock exchange listing standards following the consummation of the business combination; the risk that the business combination disrupts current plans and operations of Ribbon or DRC as a result of the announcement and consummation of the business combination; the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and retain its management and key employees; costs related to the business combination; changes in applicable laws or regulations; Ribbon's estimates of expenditures and profitability and underlying assumptions with respect to shareholder redemptions and purchase price and other adjustments; the impact of the COVID-19 pandemic; changes in laws and regulations that impact DRC; ability to enforce, protect and maintain intellectual property rights; and other risks and uncertainties set forth in the section entitled 'Risk Factors' and 'Cautionary Note Regarding Forward-Looking Statements' in Ribbon's final prospectus dated January 14, 2025 relating to its initial public offering and in subsequent filings with the SEC, including the registration statement on Form S-4 relating to the business combination expected to be filed by DRC. No Offer or Solicitation This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or an exemption therefrom. For further queries please contact: Geneva Capital Group on behalf of DRC Bob Lau, [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
